Prediction of Microvascular Invasion in Solitary AFP-Negative Hepatocellular Carcinoma ≤ 5 cm Using a Combination of Imaging Features and Quantitative Dual-Layer Spectral-Detector CT Parameters.
Academic Radiology 2023 March 23
RATIONALE AND OBJECTIVES: AFP-negative hepatocellular carcinoma (AFPN-HCC) within 5 cm is a special subgroup of HCC. This study aimed to investigate the value of dual-layer spectral-detector CT (DLCT) and construct a scoring model based on imaging features as well as DLCT for predicting microvascular invasion (MVI) in AFPN-HCC within 5 cm.
METHODS: This retrospective study enrolled 104 HCC patients who underwent multiphase contrast-enhanced DLCT studies preoperatively. Combined radiological features (CR ) and combined DLCT quantitative parameter (CDLCT ) were constructed to predict MVI. Multivariable logistic regression was applied to identify potential predictors of MVI. Based on the coefficient of the regression model, a scoring model was developed. The predictive efficacy was assessed through ROC analysis.
RESULTS: Microvascular invasion (MVI) was found in 28 (26.9%) AFPN-HCC patients. Among single parameters, the effective atomic number in arterial phase demonstrated the best predictive efficiency for MVI with an area under the curve (AUC) of 0.792. CR and CDLCT showed predictive performance with AUCs of 0.848 and 0.849, respectively. A risk score (RS) was calculated using the independent predictors of MVI as follows: RS = 2 × (mosaic architecture) + 2 × (corona enhancement) + 2 × (incomplete tumor capsule) + 2 × (2-trait predictor of venous invasion [TTPVI]) + 3 × (CDLCT > -1.229). Delong's test demonstrated this scoring system could significantly improve the AUC to 0.929 compared with CR (p = 0.016) and CDLCT (p = 0.034).
CONCLUSION: The scoring model combining radiological features with DLCT provides a promising tool for predicting MVI in solitary AFPN-HCC within 5 cm preoperatively.
METHODS: This retrospective study enrolled 104 HCC patients who underwent multiphase contrast-enhanced DLCT studies preoperatively. Combined radiological features (CR ) and combined DLCT quantitative parameter (CDLCT ) were constructed to predict MVI. Multivariable logistic regression was applied to identify potential predictors of MVI. Based on the coefficient of the regression model, a scoring model was developed. The predictive efficacy was assessed through ROC analysis.
RESULTS: Microvascular invasion (MVI) was found in 28 (26.9%) AFPN-HCC patients. Among single parameters, the effective atomic number in arterial phase demonstrated the best predictive efficiency for MVI with an area under the curve (AUC) of 0.792. CR and CDLCT showed predictive performance with AUCs of 0.848 and 0.849, respectively. A risk score (RS) was calculated using the independent predictors of MVI as follows: RS = 2 × (mosaic architecture) + 2 × (corona enhancement) + 2 × (incomplete tumor capsule) + 2 × (2-trait predictor of venous invasion [TTPVI]) + 3 × (CDLCT > -1.229). Delong's test demonstrated this scoring system could significantly improve the AUC to 0.929 compared with CR (p = 0.016) and CDLCT (p = 0.034).
CONCLUSION: The scoring model combining radiological features with DLCT provides a promising tool for predicting MVI in solitary AFPN-HCC within 5 cm preoperatively.
Full text links
Trending Papers
Management of type 2 diabetes in the new era.Hormones : International Journal of Endocrinology and Metabolism 2023 September 14
Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it.Acute and critical care. 2023 August
The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation.Journal of Intensive Care 2023 May 24
Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.JACC. Heart Failure 2023 August 26
Hypertensive Heart Failure.Journal of Clinical Medicine 2023 August 3
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain.Journal of Cardiovascular Development and Disease 2023 July 31
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app